A new biotech established by Fortress Biotech Inc. will work to produce therapeutic advances in traumatic brain injury by reducing pro-inflammatory cytokines with a pair of stem cell therapy candidates in-licensed from the University of Texas Health Science Center (UTHealth).
Cellvation Tackling Traumatic Brain Injuries With Stem Cell Therapy
Emerging Company Profile: With mononuclear stem cell therapy from University of Texas research, new company hopes to address traumatic brain injury by reducing the pro-inflammatory cytokine cascade, which exacerbates the initial injuries in severe TBI.